

Conclusion The cysts of Canal of Nuck encompass various differential diagnoses, including lymph node, cyst, inguinal hernia, infection/abscess, inguinal gonad, endometriosis, benign tumors, and neoplasia. A thorough understanding of these masses' anatomy, clinical presentation, and imaging characteristics can help avoid misdiagnosis and inappropriate treatment. Surgical intervention is considered the gold standard for managing symptomatic masses in the canal of Nuck. In some cases, conservative management with close observation may be appropriate, especially in asymptomatic or low-risk lesions.

Disclosures No disclosures

#1092 SLN, DASELER ZONES AND THE INJECTION SITES IN VULVA CANCER: SHOULD WE THINK OUTSIDE THE BOX?

^{1,2}Sally Eltabab*, ³Priyanka Reddy. ¹Churchill Gynaecology cancer center, Oxford, Oxford, UK; ²Gynaecology cancer center, ELShatby Maternity University Hospital, Alexandria, Egypt; ³Oxford University Hospitals foundation trust, Oxford, UK

10.1136/ijgc-2023-ESGO.842

Introduction/Background SLN had become the standard of care for Lymph node mapping and excision in management of vulva cancer. The technique has been adopted to minimize the morbidity associated with complete inguino - femoral dissection. Different techniques have been used, to locate the SLN, and the injection is standardized to be intra-tumoral or at the scar site.

The technique sometimes fail to locate the sentinel lymph node, and the adaptation was always in modifying the technique used, e.g. radioactive material versus methylene blue or combination of both.

Few studies examined the feasibility of injection around the scar site and found to be feasible.

The hypothesis Is it time to consider injection at the clitoris (mimicking the technique in breast cancer : peritumoral versus periareolar injection) to improve our detection rate, especially in High BMI patients.

Methodology A retrospective pilot study including 10 cases SLN detection conducted in Cancer center over a year.

The sites of sentinel lymph nodes images were reviewed and were allocated according to Daseler zones classification. The distribution was correlated to the primary tumor site, to detect the association.

Results In 1/10, no SLN was detected and complete LN dissection done.

6/10 SLN was detected in Daseler zone I (injected : 3 at perineal lesion, 2 left lesion < 2 cm from center, and 1 on right side < 2 cm from central).

2/10 SLN detected at zone IV (Injection: at perineum, and left upper side of vulva).

1/10 SLN detected at zone II (injection was at the clitoris)

Conclusion 60% of SLN were detected in Daseler zone 1 (and the injection site varied). The clitoris has good blood flow, and rich lymphatic drainage, that will improve the detection rate of SLN .

Is it time to check peritumor injection versus peri-clitoral injection ?

Disclosures No conflict of interest

#1101 DIAGNOSTIC AND THERAPEUTIC APPROACH TO VULVAR CANCER

Asma Jellouli*, Sirine Bayar, Haithem Aloui, Khaoula Magdoud, Mahdi Frikha, Mohamed Bedis Chennoufi, Hassine Saber Abouda. *Maternity and neonatology center of Tunis, Tunis, Tunisia*

10.1136/ijgc-2023-ESGO.843

Introduction/Background Vulvar cancer is a rare disease, which represents 4% of gynecological tumors with an incidence of 0.5 to 1.5 per 100,000 women per year in France. Vulvar cancers are induced in 30 to 69% of cases by the presence of papillomavirus (HPV), in particular HPV 16 and 18, and can also occur in an inflammatory context. The diagnosis is made by histological examination of a vulvar biopsy. It usually affects older women and most often develops on a pre-existing dermatosis.

Methodology The aim of this work is to know the pre-cancerous and cancerous lesions in order to contribute to a better therapeutic approach.

Our study is a retrospective study of 10 cases of squamous cell carcinoma of the vulva collected over a period of 7 years. **Results** The average age was 65.6 years with extremes ranging from 55 to 80 years. The time to consultation was very long with an average of 3.5 years.

Eighty percent of the patients had advanced tumors with an average size of 5.3 cm and in 80% of the case. Treatment was surgical in all cases, followed by radiotherapy in case of lymph node invasion and/or borderline vulvar resection. Overall survival at 5 years was 40%. The major prognostic factors were lymph node involvement and tumor size.s there were inguinal adenopathies.

Conclusion Vulvar cancer has a poor prognosis. The delay in diagnosis is a real problem despite the accessibility of the vulva. Only an earlier management is likely to improve the prognosis.

Management has evolved into a personalized multidisciplinary approach, where each therapeutic decision must be discussed in a multidisciplinary consultation meeting

Disclosures The information presented in this study is based on retrospective data and should be interpreted with caution. The findings and conclusions are specific to the study population and may not be generalizable to all cases of vulvar cancer.

#1107 THE BENEFIT OF RECONSTRUCTION IN VULVAR CANCER

Amal Mouzali*, Sarah Saidlhadj, Nabila Mechri, Youcef Tayebi. *Douera university hospital, Algiers, Algeria*

10.1136/ijgc-2023-ESGO.844

Introduction/Background Vulvar cancer is a rare pathology, which represents 4% of female genital tract tumors. It is a cancer generally affecting postmenopausal women with an average age at diagnosis of 70 years. The treatment is mainly surgical with total or partial vulvectomy associated or not with an inguinal lymphadenectomy.

In order to limit the surgical morbidity and the healing time, various techniques of pelviperineal reconstruction exist.

Methodology We present two cases of vulvar cancer, in the first case we treat the patient without vulvar reconstruction